NASDAQ:SAGESAGE Therapeutics Stock Price, Forecast & News

SAGE Therapeutics' stock was trading at $42.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SAGE stock has decreased by 11.6% and is now trading at $37.38. View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SAGE Therapeutics.

SAGE Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for SAGE Therapeutics.

SAGE Therapeutics Inc (NASDAQ:SAGE) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($2.44) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($3.17) by $0.73. The biopharmaceutical company earned $2.29 million during the quarter, compared to analyst estimates of $2.81 million. SAGE Therapeutics had a negative net margin of 7,406.75% and a negative return on equity of 63.13%. The company's quarterly revenue was up 391.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.37) EPS. View SAGE Therapeutics' earnings history.

18 Wall Street analysts have issued 12 month price targets for SAGE Therapeutics' shares. Their forecasts range from $28.00 to $263.00. On average, they expect SAGE Therapeutics' stock price to reach $82.11 in the next year. This suggests a possible upside of 119.7% from the stock's current price. View analysts' price targets for SAGE Therapeutics.

Press coverage about SAGE stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SAGE Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutSAGE Therapeutics.

Some companies that are related to SAGE Therapeutics include Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), Zai Lab (ZLAB) and Evotec (EVTCY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), salesforce.com (CRM) and Johnson & Johnson (JNJ).

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital International Investors (7.08%), BlackRock Inc. (5.29%), Invesco Ltd. (3.39%), State Street Corp (3.25%), JPMorgan Chase & Co. (2.71%) and Janus Henderson Group PLC (2.67%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View institutional ownership trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Franklin Resources Inc., Frontier Capital Management Co. LLC, Bank of New York Mellon Corp, Pictet Asset Management Ltd., Invesco Ltd., Nuveen Asset Management LLC, and Capital International Investors. View insider buying and selling activity for SAGE Therapeutics.

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, Two Sigma Advisers LP, Victory Capital Management Inc., Victory Capital Management Inc., Voloridge Investment Management LLC, and Casdin Capital LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas. View insider buying and selling activity for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $37.38.

SAGE Therapeutics has a market capitalization of $1.94 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.

The official website for SAGE Therapeutics is www.sagerx.com.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]